for any avoided severe complication. In the univariate sensitivity analysis the ICER result was especially sensible to CA total cost and in a lesser extension to MICS total costs. The probabilistic sensitivity analysis shows the robustness of the results. The 37.8% of the results were cost saving respect to CA. The Willingness To Pay (WTP) acceptability curves show that MICS compared to CA, had a higher probability to be accepted for the all the WTP values above US$16.000. ConClusions: MICS shows a better cost-effectiveness ratio than CA, with an ICER of US$8.326. The univariate sensitivity analysis shows the ICER result was especially sensible to CA total costs. The probabilistic analysis shows that in 36.8% of Monte Carlo simulations, MICS was cost saving respect to CA.
objeCtives: To compare clopidogrel/aspirin with ticagrelor/aspirin in terms of costs and effects, from the perspective of the Mexican public health care system. Methods: A markov model was designed to take into account all relevant outcomes reported in the PLATO study, allowing the evaluation of two different cohorts of patients according to their renal function (< 60 mL/min creatinine clearance and ≥ 60 mL/min). The effectiveness measures analyzed were life years gained and events (bleeding, stroke and MI) averted. Annual cost of antiplatelet therapy was estimated with unit prices of the IMSS, while costs of diseases were taken from DRGs of the IMSS. 5 years horizon was used, so future costs were discounted at 5% discount rate. Probabilistic sensitivity analysis was performed with 1000 iterations via Monte Carlo simulations. Results: Total expected costs per patient were US$17,121 and US$17,697 respectively for both cohorts of clopidogrel while the costs for the two cohorts of ticagrelor were US$18,430 and US$18,261 respectively. The treatment with clopidogrel resulted in less outcomes per patient (bleeding: 0.67 and 0.55; stroke: 0.09 and 0.083; MI: 0.51 and 0.49) than ticagrelor (bleeding: 0.76 and 0.59; stroke: 0.1 and 0.085; MI: 0.53 and 0.5); therefore the pharmacoeconomic profile of clopidogrel in comparison with ticagrelor is more favorable in the current study. Sensitivity analysis showed that clopidogrel has a higher probability of being a cost-saving option versus ticagrelor for both cohorts of patients. ConClusions: The economic evaluation of clopidogrel/aspirin versus ticagrelor/aspirin, taking into account relevant outcomes as well as primary endpoints of clinical trials, has proven that cost-effectiveness results may vary depending of the renal function of patients, thus giving a broader picture of the problem to decision makers. objeCtives: To compare the incremental cost-effectiveness ratio (ICER) of the reversible direct thrombin inhibitor dabigatran 150mg BID with those of the Xa factor inhibitors rivaroxaban and apixaban from the Mexican public health institution perspective. Methods: The ICER´s were calculated using a Markov model with a 10-year time horizon for patients over 65 and diagnosed with atrial fibrillation. Each treatment arm started with a cohort of 10,000 patients. The clinical events tracked were incorporated: ischemic stroke, systematic embolism, transient ischemic stroke, hemorrhagic stroke, intracranial hemorrhage, extracranial hemorrhage, acute myocardial infarction, minor bleed and death. Transition probabilities were calculated based on indirect comparisons of published phase III clinical trials. Costs are adapted to the Mexican public health institution perspective. Costs were calculated using published literature, and national costs taken from pharmaceutical companies and public health institutions. Cost-effectiveness was based on the 1GDP per capita threshold established by the National Health Council in Mexico. Costs and outcomes were discounted at a 5% annual-rate. Deterministic and probabilistic sensitivity analyses were performed to evaluate the uncertainty of the variables. Results: Dabigatran was found to be dominant when compared with rivaroxaban and apixaban. A reduction on risk for cardiovascular complications was the key advantage of dabigatran. Dabigatran was also more effective when compared with warfarin (69,435 vs. 68,373 life years gained) although more costly (USD$192.76 vs USD$190.73 million dollars). The ICER was USD $1,910.43 per life year which is considered highly cost-effectiveness. The Incremental Cost-Utility Ratio per QALY gained was USD$1,549.00. ConClusions: The ICER and ICUR of Dabigatran are well below 1GDP (USD$ 10,483.26) per capita versus warfarina. Dabigatran was found to be dominant in comparison with all other treatments. As such, dabigatran can be considered a very cost-effective intervention for the Mexican population over 65 with atrial fibrillation. objeCtives: To identify the incremental cost-effectiveness ratio (ICER) for the treatment of inoperable patients with severe symptomatic aortic valve stenosis (SAS) using transcatheter aortic valve replacement (TAVR), compared to the standard of care (SoC), from the Mexican public payer perspective. Methods: A previously published decision analytical model was adapted to the Mexican setting to predict clinical endpoints and costs over 10 years and discounted at 5%. Mexican epidemiological data were applied. We performed a systematic review of published clinical trials to obtain the necessary clinical information to evaluate the impact of TAVR and SoC in the short and long term evolution of patients. Direct public health care costs were estimated from published literature and governmental databases. Resource utilization patterns were derived from Mexican Clinical Practice Guidelines. The ICER was computed as incremental cost per life-year gained (LYG). Probabilistic and deterministic sensitivity analyses were conducted to estimate the confidence around the results. Results: Over the time horizon, compared to SoC, TAVR produced an additional 1.61 Life years at an additional cost to the health care sector of $777,414 MXP. The ICER was thus $483,022 MXP (35,779 USD) per LYG. The sensitivity analysis identified time horizon, discount rate on health benefits, probability of leaving intensive care and time of stay in intensive care, as the variables with the most impact. The model was insensitive to changes in the TAVR acquisition cost, device related complication rates and the probability/ cost of additional pacing. ConClusions: In comparison with SoC, TAVR produces an increase in life expectancy in patients with SAS that are ineligible for cardiac surgery, at an ICER below an internationally accepted cost-effectiveness threshold value. These results, and the improvements in health and quality of life observed in the clinical studies, identify TAVR as both a clinically effective and cost-effective therapy for Mexican patients. objeCtives: Atrial Fibrillation (AF) affects 1-2% of the population, and this figure is likely to increase in the next 50 years. AF is associated with increased rates of death, stroke and other thromboembolic events, heart failure and hospitalizations, degraded quality of life and reduced exercise capacity. It is suggested that patients with AF should be stratified for the risk of stroke and bleedings and that most should receive antithrombotic therapy. The aim of this study was to assess the cost-effectiveness (CE) of Apixaban against other anticoagulation therapies for prevention on non-valvular atrial fibrillation (NVAF), from the private health care perspective. Methods: A simulated cohort of 1000 patients with NVAF entered a decision-tree model to compare costs and effectiveness of Warfarin (5 mg/24 hours), Apixaban (5 mg/12 hours), Dabigatran (110 mg/12 hours and 150 mg/12 hours), and Rivaroxaban (20 mg/24 hours). Effectiveness measures were: stroke, bleeding, myocardial infarction (MI) rates and deaths. Local costs were gathered from Guatemala's official databases (US$, 2013) and only direct medical costs were considered. The model used a lifetime horizon with a 5% discount. Results: Apixaban was the only treatment that consistently prevented all four considered diseases: 3 MIs, 4 strokes, 85 bleedings and 1 SE avoided when compared to Warfarin. Overall costs were US$33708.34 for warfarin, US$24538.68 for Apixaban, US$24757.57 for Dabigatran 110 mg, US$24198.23 for Dabigatran 150 mg, and US$24252.46 for Rivaroxaban. In terms of QALY's, Apixaban earned the highest amount with 5.740, followed by Rivaroxaban, Dabigatran 150 mg, Dabigatran 110 mg and Warfarin. In the CE incremental analysis, Apixaban was a cost-effective option. Apixaban obtained the highest probability of being cost-effective (45%) with a 3 GPB per capita in Guatemala. ConClusions: Apixaban is a Cost-Effective option for the Guatemala's Private Health System. San. Ltd. Sti., Istanbul, Turkey, 2 Yorum Consultancy, ISTANBUL, Turkey, 3 Medical Park Hospital, Istanbul, 4 Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey, 5 Yeditepe University Hospital, Istanbul, Turkey, 6 9 Eylül Faculty of Medicine, Izmir, Turkey, 7 Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 8 Gazi University, Ankara, Turkey objeCtives: To evaluate the cost-effectiveness of rivaroxaban in addition to the standard of care (SoC) therapy in the prevention of the risk of CV events and bleeding in patients with a recent ACS compared to the placebo in addition to the SoC. Methods: A Markov model demonstrating the progression of ACS patients from healthy state towards atherosclerotic and bleeding events and to death was adapted to the Turkish setting. The cycle length was set as six-months. The analysis was undertaken from a payer perspective. Event rates and treatment effects were derived from the ATLAS-2-TIMI clinical trial. 61Utility values for events were based on international literature. Costs of each health state included year 2013 local costs of medications, monitoring and events (TL/ USD currency rate was set at 1.70; mid 2013). Incremental cost effectiveness ratios (ICER) per life year (LY) and quality-adjusted LY (QALY) gained were calculated. One-way sensitivity analyses were conducted to test the robustness of the model. The time horizon was life time period. Discount rate was set at 3.5% for economic and clinical inputs. Willingnessto-pay (WTP) threshold was set as twice the local gross domestic product per capita (20,888USD). Results: The total cost of rivaroxaban-treated patients was 578USD higher compared to SoC. Additional drug costs (676USD) caused by rivaroxaban was somewhat offset by reduced costs of and events and interventions (98USD). Moreover, rivaroxaban was associated with increments of 0.102LYs and 0.088QALY leading to an ICER of 5,691USD/LY gained and 6,590USD/QALY gained. Sensitivity analyses showed that the cost-effectiveness results are fairly insensitive to most inputs. ConClusions: Rivaroxaban, given its cost-saving effects on consequent CV events, improvement in LYs and QALYs, and ICER values below WTP threshold, is suggested to be a cost-effective alternative for the prevention of CV events in ACS.
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